

December 10, 2021

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

**Notice Regarding Launch of
3 Ingredients / 5 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 3 ingredients / 5 products of generic drugs today on December 10, 2021 as below.

New products list

Classes	Product Name	Original Brand Name
Endothelin receptor antagonist	AMBRISENTAN Tablets 2.5mg "KMP"	Volibris® Tablets 2.5mg
Anti-allergic ophthalmic solution	OLOPATADINE Ophthalmic Solutions 0.1% "SANWA"	Patanol® Ophthalmic Solution 0.1%
Anti-epileptic agent	LEVETIRACETAM TABLETS 250mg/500mg "TOWA"	E Keppra® Tablets 250mg/500mg
	LEVETIRACETAM DS 50% "TOWA"	E Keppra® Dry syrup 50%